12:00 AM
 | 
Jul 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Vpriv velaglucerase alfa: Additional Phase III data

Additional data from the double-blind, international Phase III HGT-GCB-039 trial in 34 treatment-naïve patients with Type I Gaucher's disease showed that 60 U/kg IV Vpriv every other week significantly increased lumbar spine bone mineral density (BMD), as measured by dual-energy x-ray absorptiometry (DEXA scan) Z-scores, from baseline to 9 months vs. Cerezyme imiglucerase. Specifically, Vpriv increased mean lumbar spine BMD Z-score from baseline to 9 months...

Read the full 318 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >